BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB: IXSBF)(TSX VENTURE: IXS)(http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL™), announced today the company has presented new in vivo proof of principle data at the American Association for Cancer Research (AACR) Annual Meeting 2008 in San Diego, California.
